评论:临床决策是否应考虑药物基因组学证据?聚焦部分心血管药物
本文讨论药物基因组学在临床实践中推广的障碍,包括缺乏前瞻性随机对照试验验证临床结局效用、临床算法不明确及成本效益问题。作者将CPIC推荐证据与常见临床实践指南及FDA标签推荐证据类比,列举药物相互作用、药物-基因相互作用、治疗范围选择及基于患者因素的剂量调整等心血管治疗示例。
要点
- CPIC推荐证据与许多常见临床实践指南证据水平相似。
- 药物基因组学推广障碍包括缺乏前瞻性RCT和成本效益数据。
- 心血管药物示例涉及DDI、药物-基因相互作用及剂量调整。
核心结论
- 支持CPIC推荐的证据与许多常见临床实践指南及FDA标签推荐的证据类型和水平相似。
研究设计与样本
- 本文为评论性文章,通过类比分析CPIC推荐与常见临床实践指南及FDA标签推荐的证据支持情况。
主要发现
- 药物基因组学广泛临床应用延迟的障碍包括缺乏前瞻性随机对照试验、临床算法不明确及成本效益未知。
- 许多常见临床实践推荐由与CPIC推荐相似水平证据支持。
临床怎么用
- 临床决策中可参照CPIC推荐,类比常见实践指南证据水平进行药物基因组学应用。
局限性
- 缺乏前瞻性随机对照试验验证药物基因组学对临床结局的效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite advances in technology and guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC) that focus on how to use pharmacogene test results, hurdles remain that have delayed the widespread application of pharmacogenomics in clinical practice. These hurdles include a lack of prospective randomized controlled trials to address the utility of pharmacogenomics on clinical outcomes, what the clinical algorithm for pharmacogenomics should be, and whether pharmacogenomics is cost-effective. However, the implementation of clinical practice guidelines, such as those from professional organizations, is commonplace and often termed the application of evidence-based medicine. Here, we draw an analogy between the evidence supporting many commonly cited clinical practice guidelines and U.S. Food and Drug Administration-approved labeling recommendations and the evidence supporting recommendations from CPIC. Although many clinical practice guideline recommendations are supported by the results of randomized controlled clinical trials, we cite examples of common clinical practices that are supported by levels and types of evidence similar to the evidence supporting many of the CPIC recommendations. Specifically, we discuss clinical recommendations for guidance related to drug-drug interactions, drug-gene interactions, therapeutic range selection, and dosage adjustments based on patient-specific factors within the context of a select set of cardiovascular therapeutic topics.
引用
- Bottorff MB, Bright DR, Kisor DF, et al. Commentary: Should Pharmacogenomic Evidence Be Considered in Clinical Decision Making? Focus on Select Cardiovascular Drugs. Pharmacotherapy. 2017. PMID: 28654154. doi:10.1002/phar.1979
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。